FORMULATION AND IN VITRO – IN VIVO PHARMACOKINETIC EVALUATION OF CARDIOVASCULAR DRUG LOADED PULSATILE DRUG DELIVERY SYSTEMS

Authors

  • KUMAR BABU PASUPULETI Department of Pharmaceutics, Pacific Academy of Higher Education and Research University, Udaipur, India
  • VENKATACHALAM A. Department of Pharmaceutics, Pacific Academy of Higher Education and Research University, Udaipur, India
  • BHASKAR REDDY KESAVAN Department of Pharmaceutics, Centre of Pharmaceutical Nanotechnology, Sri Venkateswara College of Pharmacy, RVS Nagar, Chittoor, India

DOI:

https://doi.org/10.22159/ijap.2021v13i6.42607

Keywords:

Liquid Solid composite, Compresses tablet, Optimization, Disintegration time, wetting time

Abstract

Objective: This study is to formulate Nebivolol into a Pulsatile liquid solid composite compression coated tablet, which will delay the release of the drug in early morning hypertension condition.

Methods: The liquid solid composite tablet was formulated and compressed with ethyl cellulose coating polymer. The percent invitro drug release of the liquid solid composite compressed tablet was tested. Based on disintegration time and wetting time, the LCS2, LCS3, LSC6, LCS7 and LCS12 formulations were found to be the optimized solid liquid compacts fast dissolving core tablet formulations, which may be excellent candidates for further coating with polymer to transfer into press coated pulsatile tablet formulations. Coating the core tablet with varying ethyl cellulose concentrations resulted in five different formulations of pulsatile press-coated tablet (CT1, CT2, CT3, CT4, CT5). in vitro drug release, in vitro release kinetic studies, in vivo pharmacokinetic and stability tests were all performed for  the prepared pulsatile press coated tablet.  

Results: CT3 tablets are coated with ethyl cellulose polymer, which shows maximum controlled drug release from the core tablet i.e. 96.34±1.2% at 8th h. It shows there was an efficient delay in drug release form core tablet i.e. upto 3 h, followed by the maximum amount of drug release of 96.34±2.4 at 8h.Which shows the core drug will be more efficiently protected from the gastric acid environment 1.2 pH, duodenal environment 4.0 pH and release the drug only in the small intestine

Conclusion: According to the findings, CT3 Pulsatile press coated tablet increased the bioavailability of Nebivolol by 3.11 percent.

Downloads

Download data is not yet available.

References

Patel BB, Shah CN. Recent research on liquid solid technology for solubility enhancement-a review. Int J Adv Pharm 2016; 5:1-7.

Sowmya P, Venkatesh DP, S. Nayek. Pulsatile drug delivery system: a formulation approach for treatment of diseases. Int. J. Curr. Pharm. Res. 2020;12:16-21.

Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, Gazzaniga A. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J Control Release 2001;73:103-10.

Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on Biopharmaceutics classification system: basic approaches and practical applications. Int. J. Pharm 2011; 420:1–10.

Nil Kumar J Shinde, Nidhi S Patil, Trupti S Jadhav, Harinath N More. Design and development of floating pulsatile drug delivery of losartan potassium. Int J App Pharm 2020; 12: 218-227.

Mohamad A, Dashevsky A. pH-independent pulsatile drug delivery system based on hard gelatin capsules and coated with aqueous dispersion Aquacoat ECD. Eur J Pharm Biopharm 2006; 64:173-9.

Khan Z, Pillay V, Choonara YE, Du Toit LC. Drug delivery technologies for chronotherapeutic applications. Pharm Dev Technol 2009;14:602-12.

Vishal V, Bilaskar, Indrajeet S Patil, Omkar A patil, Girishchandra R Mandke, Shrinivas K Mohite. Design, development and optimization of pulsatile drug delivery of antihypertensive drug. International research journal of pharmaceutical and biosciences 2018; 4(6):12-19.

Anil A, Thomas L, Sudheer P. Liquisolid compacts: an innovative approach for dissolution enhancement. Int J Pharm Pharm Sci 2018; 10:1-7.

Dalvi PB, Ingale PR. Liquisolid technique: an approach for enhancement of solubility. World J Pharm Sci 2014; 3:434-46.

Spireas S, Bolton M. Liquisolid systems and methods of preparing same, U. S. Patent 5 1999; 968:550.

Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int. J. Pharm. 2007; 341: 26–34.

Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN, Bhise SB. Liquisolid tablets: a novel approach for drug delivery. Int J Health Res 2009;2:45-50.

Bauskar Mohit D, Nandedkar S.Y, Wagh Rajendra D. Formulation design and optimization of pulsatile release tablet of acebrophlline with swelling and erodible layers for treatment of nocturnal bronchial asthma. Int. J. Pharm. Sci. Res 2011; 2: 3100-08.

Golla chandramouli, Agaiah Gouud B, Mallikarjun B, Srikanth L. Design and Evaluation of Press coated pulsatile delivery of Doxofylline tablets. Acta sci. pharm. sci. 2018; 2: 58-62.

Haritha B. A review on an evaluation of tablets. J Formulation Sci Bioavailability 2017;1:1-5.

Uddin MS, Mamun AA, Tasnu T, Asaduzzaman M. In-process and finished products quality control tests for pharmaceutical tablets according to pharmacopoeias. J Chem Pharm Res 2015;7:180-5.

Yadav AV, Shete AS, Dabke AP. Formulation and evaluation of orodispersible Liquisolid Compacts of Aceclofenac. Ind J Pharm Edu Res 2010;4: 227-35.

Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquidsolid tablets formulation: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2008;69: 993-1003.

Sanjayamitra PVSS, Ganesh GNK. Dissolution and solubility enhancement strategies: current and novel prospectives. J Crit Rev 2018;5:1-10.

Balaji Maddiboyina, Ramya Krishna Nakkala, Kokkilagada Vinod kumar. Preparation and evaluation of esmeprazole enetriccoated tablets. Int. J. Pharm. Pharm. Sci. 2020;18:16-30.

Basawaraj S Patil, Abhishek M Motagi, Upendra Kulkarni, Hariprasanna RC, Shivan and Patil A. Development and evaluation of time controlled pulsatile release Lisinopril tablets. J Bio Sci Res. 2012;2:30-5.

Bhupendra Singh, Geetanjali Singh, Manish Vyas, Surajapal Verma, Sourav thakur. Optimized chronomodulated dual release bilayer tablets of fexofenadine and montelukast: quality by design, development, and in vitro evaluation. Future J Pharm Sci 2019; 5: 1-20.

Raghavender Chenna, Padmanabha reddy Y. Formulation and in vivo evaluation of chronomodulated drug delivery of Nimodipine. Int j pharm sci drug res 2019; 11: 325-29.

Sangram M, Patil, Rajesh V, Mishra, Satish V, Shirolkar. Development and evaluation of sustained released simvastatin pellets. Research journal of pharmacy and development 2017; 10: 2467-73.

Rajab NA. Preparation and in vitro evaluation of lacidipine oral liquid solid tablet as an approach of solubility and dissolution rate enhancement. Int J Appl Pharm 2018;10:145-53.

Lemmer B. Chronopharmacokinetics: implications for drug treatment. J. Pharm. Pharmacol. 1999; 51:887–890.

Raimar Löbenberga Jae Seung Kimb Gordon L Amidon. Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. Eur. J. Pharm. Biopharm. 2005; 60:17-23.

Mohd Javed Qureshi, Javed Ali, Sanjula Baboota, Alka Ahuj and Chitneni,Mallikarjun. Pharmacokinetic Study of a Capsule-based Chronomodulated Drug Delivery System of Salbutamol Sulphate in Rabbits. Trop. J. Pharm. Res. 2014; 13: 17-22.

Chauhan SK, Tyagi A, Singh B, Agarwal S. Accelerated stability studies of a polyherbal preparation (eazmov(r)) capsule. Anc Sci Life 1999;18:210–7.

Shrivastava AR, Ursekar B, Kapadia CJ. Design, optimization, preparation and evaluation of dispersion granules of valsartan and formulation into tablets. Curr Drug Deliv 2009;6:28‑37.

Published

06-09-2021

How to Cite

PASUPULETI, K. B., A., V., & KESAVAN, B. R. (2021). FORMULATION AND IN VITRO – IN VIVO PHARMACOKINETIC EVALUATION OF CARDIOVASCULAR DRUG LOADED PULSATILE DRUG DELIVERY SYSTEMS. International Journal of Applied Pharmaceutics, 13(6). https://doi.org/10.22159/ijap.2021v13i6.42607

Issue

Section

Original Article(s)